NecstGen

What does it take to bring a cell or gene therapy to patients? Have you ever wondered what it means to develop viral vectors, cell therapies, (ex vivo) gene therapies, and more? Watch the video. Bringing a product from R&D to production takes work. When developing a cell therapy, for example, we very closely examine the processes that our client has developed so far. We go through them, identify the critical process steps, and adjust them to achieve a GMP-compliant manufacturing process. But what is the most critical aspect of it all? We operate at the edge of scientific discovery, always keeping the patient at the centre. NecstGen helps academic and industrial Cell and Gene Therapy developers enter the clinical stage by bringing together the required expertise from R&D, development, production, QA, QC, and regulatory affairs in a 4,000 m2 development and GMP manufacturing facility. Watch the video and start exploring how we bring CGTs closer to the patients who need them. #celltherapy #genetherapy #viralvector #cdmo

In collaboration with bioMérieux, NecstGen is enhancing CGT development with bioMérieux’s Rapid Sterility Testing Solutions. This partnership combines NecstGen's CGT expertise with bioMérieux's innovative tools, supporting manufacturers and researchers in navigating the complexities of advanced therapies with greater efficiency. Together, we're breaking down bottlenecks in product and process monitoring, ensuring GMP compliance while addressing industry challenges like sample sacrifice and complex compositions. By accelerating testing and reducing vein-to-vein time, we're working to make critical treatments more accessible for patients. Experience bioMérieux Pharma Quality Control solutions in NecstGen's Cell Therapy Suites, Development Laboratories, QC, Microbiology, and PCR Laboratories. Contact us to learn more.

From November 4-6, Sophia Kolbe will represent NecstGen at BIO-Europe, Europe's premier autumn event for life sciences, celebrating its 30th anniversary this year. BIO-Europe gathers over 5,500 biotech, pharma, and investment professionals for an intensive schedule of 30,000+ one-to-one meetings, providing an unmatched platform for life sciences dealmakers to connect, exchange ideas, and explore strategic partnerships. With this year's theme, "Collaborative Innovation," the event also dives into the latest industry advancements and promising future of Cell and Gene Therapies being particularly discussed in the panel discussion ""Under Attack": Can cell and gene therapy revolutionise the rules of healthcare?" on Tuesday, November 5th (4 - 4.45 PM). Sophia is excited to connect with fellow innovators committed to advancing healthcare and NecstGen's mission in Cell and Gene therapy development. If you're attending, be sure to connect with Sophia and explore how we can shape the future of Cell and Gene Therapies together! Connect with Sophia on LinkedIn or schedule a partnering meeting using the link below:  https://lnkd.in/eStPrhVi

Lentivirus (LVs) are widely used for Ex-vivo Gene Therapy applications, such as CAR-T cell therapies. However, the high cost of LV manufacturing remains a significant challenge in the field, especially for cGMP manufacturing. Reducing these costs, while maintaining high-quality production, is critical for making these therapies more accessible to patients. NecstGen's mission is to challenge the manufacturing costs of Cell and Gene Therapies. We know that each client has its own individual needs, and this is why flexibility is key for us. For LVs, we offer tailor-made development and cGMP manufacturing solutions aiming to increase viral vector yields and streamline workflows. By applying Design of Experiments (DOE) methodologies, combined with access to different bioreactor technologies, our team focuses on reducing manufacturing costs while ensuring efficiency, scalability, and quality. Are you curious about how we apply these strategies to increase cost-efficiency? If so, join our webinar "Reducing Lentivirus Costs: A DOE Case Study", where you will gain valuable insights into how DOE can make lentivirus-based therapies more affordable and accessible. Don't miss this opportunity to learn from our experts and ask your questions! https://lnkd.in/eeMwP7yg

We’re excited to be attending this year’s European Society of Gene and Cell Therapy Congress in Rome, where the phrase “all roads lead to Rome” perfectly captured the spirit of this year’s event during the opening ceremony. With the highest number of attendees ever, ESGCT 2024 is proving to be an incredible gathering of Cell and Gene therapy experts worldwide. Tristan Pritchard-Meaker, André Soares, Sophia Kolbe, and Diederik Lokhorst are all here, and we’re enthusiastic to have shared Diederik’s poster on "Cost reduction of lentivirus manufacturing for CAR T by transfection optimisation to minimise the required quantity of plasmid DNA using Design of Experiments during yesterday’s poster session. We’ll be at our booth #A20 for the rest of the conference. If you haven’t already, stop by for a chat—we’d love to connect & discuss how NecstGen’s expertise can support your Cell and Gene therapy development.

Will we see you at the ESGCT Conference in Rome this week?   The European Society of Gene and Cell Therapy Congress is one of the most anticipated Cell and Gene Therapy events, bringing together leading experts to discuss the latest advancements in the field.   Tristan Pritchard-Meaker, André Soares, Sophia Kolbe, and Diederik Lokhorst will be attending the conference. Meet the team throughout the conference at booth #A20.   On Tuesday, October 22nd (19:30 – 21:00), Diederik will present his poster #P0507 “Cost reduction of lentivirus manufacturing for CAR T by transfection optimisation to minimise the required quantity of plasmid DNA using Design of Experiments”. Plasmid DNA is expensive representing a significant amount of the Cost of Goods (COG). Diederik research shows how our team applies Design of Experiments (DOE) to reduce the COG and supports making lentivirus-based therapies more affordable.   If you're attending #ESGCT2024, we'd love to connect. Be sure to stop by NecstGen’s booth and Diederik's poster and say hello!

Thank you for attending The CGT Circle Event hosted by NecstGen! This week, we were honoured to host another CGT Circle event at our facility in Leiden supporting the initiative dedicated to empowering women in Cell & Gene Therapy and harnessing their collective power by de-centralised networking. The event featured a range of inspiring presentations and insightful discussions. Françoise Carlotti provided an overview of the latest developments in regenerative medicine, sharing progress on her own research developing iPSC-derived islet cells for diabetes treatment. Maria Gomes Fernandes, PhD offered practical advice on career transitions, highlighting her own journey from academia to industry. Rachel Abbott discussed the unexpected twists in her career path that led her from post-doc to CEO at Pan Cancer T. Ester Weijers emphasised the importance of embracing challenges, drawing from her personal experience along her career path from MBO to CEO. The subsequent Q&A session allowed diving deeper into these topics, with discussions ranging from overcoming barriers in leadership roles to exchanging practical strategies for advancing their careers in Cell & Gene Therapy. After that, Veronique van de Sande provided a refreshing session on how to improve one’s communication skills sharing refreshing insights, tips, and food for thought resonating with the audience.  The following networking reception offered a great opportunity to connect and continue engaging discussions. Kudos to our esteemed colleague Sophia Kolbe for organising the exciting program and moderating. Many thanks to all our speakers for their insightful contributions. Events like these are vital to driving progress and creating lasting connections. Please enjoy a selection of photos capturing the day's highlights. We look forward to future opportunities to connect and collaborate. We invite you to stay connected with NecstGen and follow The CGT Circle for updates on future events and initiatives. #necstgen #cgtcircle #celltherapy #genetherapy #womeninscience

We are pleased to announce the release of a technical note highlighting an innovative approach to quality control testing in CAR T cell therapy manufacturing. Title: CAR T Lentiviral Vector Expression Testing, Identity, and Purity Assessment Throughout the Cell Therapy Manufacturing Process A Collaboration Between Accellix, NecstGen, and bioMérieux This work was co-authored by Óscar Bártulos, Jacob van Vloten, Félix A MONTERO-JULIAN PhD, Melissa Van Pel, and Christian Aguilera-Sandoval. In Cell and Gene Therapies, robust quality control is essential to meet regulatory standards and ensure product safety and efficacy. This note explores how the Accellix automated cartridge-based flow cytometry platform was evaluated for assessing CAR T cell identity and purity, comparing its performance with conventional flow cytometers. Using a lentiviral vector to express enhanced green fluorescent protein (eGFP) as a reporter gene, we demonstrated that Accellix's platform can reliably support early-stage CGT manufacturing and quality control, offering a reproducible and efficient solution for critical process steps. The collaboration showcases NecstGen’s role as a center of excellence for Cell and Gene Therapies, working alongside bioMérieux’s diagnostic expertise and Accellix’s innovative cytometry technology to enhance the manufacturing workflow for adoptive T cell therapies. Read the full technical note to explore our findings and insights on leveraging advanced cytometry platforms for quality control in Cell and Gene Therapy. Receive a copy by emailing us at bd@necstgen.com or simply comment below, and we’ll reach out!

By combining our CGT expertise with bioMérieux’s comprehensive Environmental Monitoring and Endotoxin Testing Solutions, we’re empowering researchers and manufacturers to tackle the unique challenges of advanced therapies. This partnership enhances process efficiency and helps us bring critical treatments to patients faster. Together, we’re addressing industry challenges like sample complexity and emphasizing sustainable practices and GMP compliance to ensure quality at every stage. You can experience these solutions from bioMérieux Pharma Quality Control at NecstGen's Cell Therapy Suites, Development Laboratories, QC, Microbiology, and PCR Laboratories.

Are you curious about how cost reductions in Cell & Gene Therapy manufacturing can be achieved? Join us for our upcoming webinar led by Diederik Lokhorst, Viral Vector Specialist, where we’ll discuss:   Title: “Reducing Lentivirus Costs: A DOE Case Study”   Lentivirus (LV) is the commonly used gene delivery system for CAR T therapies. LV is typically produced using a transient transfection method inserting relevant plasmid DNA constructs into the producer cell. Plasmid DNA is expensive representing a significant amount of the Cost of Goods (COG). Diederik will share how our team applies Design of Experiments (DOE) to reduce the COG and supports making lentivirus-based therapies more affordable.   Who should attend? This webinar is tailored for academic research groups, biotech companies, and industry leaders in Cell and Gene Therapies interested in learning how one can use DOE as a tool to drive cost-efficiency in LV manufacturing.   What to expect? An inside look at transfection-based lentivirus manufacturing DOE as a tool to understand and improve your manufacturing process Case Study: Transfection of T Cells with LV   As a CDMO, NecstGen is committed to continuous improvement, ensuring our partners receive efficient, high-quality manufacturing services. Join us to learn how our strategies can help make lentivirus-based therapies more cost-efficient.   Ready to Attend? Secure your spot today by registering now!   For questions, connect with our BDs Tristan Pritchard-Meaker, Sophia Kolbe, or André Soares.